Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

D 3263

Drug Profile

D 3263

Alternative Names: D-3263; D-3263 HCl; EC D-3263 HCl; Enteric coated D-3263 HCl; TRPM8

Latest Information Update: 28 Apr 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dendreon Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; TRPM8 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Benign prostatic hyperplasia; Solid tumours

Most Recent Events

  • 31 Dec 2013 Suspended - Phase-I for Solid tumours in USA (PO)
  • 31 Dec 2013 Suspended - Preclinical for Benign prostatic hyperplasia in USA (PO)
  • 01 Dec 2011 Dendreon completes its phase I trial for Solid tumours in USA (NCT00839631)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top